New TTT1 trial set for Institute of Cardiovascular and Medical Sciences in 2020

Staff within the Institute of Cardiovascular and Medical Sciences are eagerly anticipating the initiation of a pioneering new global type 1 diabetes trial.Image of finger prick with a blood spot

The TTT1 trial – funded by the Juvenile Diabetes Research Foundation (JDFR) the leading global organisation who fund research to cure, treat and prevent type 1 diabetes, will be co-led by State University of New York and will begin in Scotland in early 2020. JDRF have described the trial as “the single most advanced drug-based study to date in type 1 diabetes”.

The TTT-1 trial is led by Dr John Petrie, Professor of Diabetic Medicine, Institute of Cardiovascular and Medical Sciences. Dr Petrie said: “The hope is to use the combination therapy of dapagliflozin and semaglutide to reduce HbA1c to less than 7% in the majority of people with type 1 diabetes; and since these drugs have benefits for the heart and can also induce weight loss, there may be additional advantages of this drug combination, which would be very positive for those with the condition.

First published: 6 December 2019